组织学检查淋巴结阳性的子宫内膜癌患者的复发率、部位、时间及临床结局：一项意大利双中心回顾性研究
Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study.
作者信息
Gadducci Angiolo, Guerrieri Maria Elena, Cosio Stefania, Fabrini Maria Grazia, Laliscia Concetta, Attianese Daniela, Rossi Annalisa, Ferrero Annamaria
机构信息
Department of Experimental and Clinical Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy
Department of Experimental and Clinical Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy.
出版信息
Anticancer Res. 2018 Mar;38(3):1695-1703. doi: 10.21873/anticanres.12403.
BACKGROUND/AIM: To assess the patterns of recurrence of node-positive endometrial cancer patients.
PATIENTS AND METHODS
This investigation assessed 82 patients who received different postoperative treatments.
RESULTS
Recurrence developed in 36 patients after a median time of 13.5 months, and involved the vagina, pelvic nodes, para-aortic nodes and distant sites in 5, 8, 16 and 17 patients, respectively. Five-year progression-free survival (PFS) and 5-year overall survival (OS) were 51.1% and 59.8%. PFS and OS were significantly better for endometrioid than for non-endometrioid tumors. There was a trend towards a better outcome for patients who underwent chemotherapy±radiotherapy compared to those who received radiotherapy alone. Among the former, there was a better 5-year PFS (65.8% versus 33.7%, p=0.038) in patients who received platinum/paclitaxel-based regimens compared to those who received platinum-based chemotherapy.
CONCLUSION
Disease recurred in 43.9% of patients, and platinum/paclitaxel-based chemotherapy plus radiotherapy appeared to be the best adjuvant treatment.
背景/目的：评估淋巴结阳性子宫内膜癌患者的复发模式。
患者与方法
本研究评估了82例接受不同术后治疗的患者。
结果
36例患者出现复发，中位复发时间为13.5个月，其中分别有5例、8例、16例和17例患者复发部位为阴道、盆腔淋巴结、腹主动脉旁淋巴结和远处转移。5年无进展生存率（PFS）和5年总生存率（OS）分别为51.1%和59.8%。子宫内膜样癌的PFS和OS显著优于非子宫内膜样肿瘤。与单纯接受放疗的患者相比，接受化疗±放疗的患者预后有更好的趋势。在前者中，接受铂类/紫杉醇方案化疗的患者5年PFS（65.8%对33.7%，p=0.038）优于接受铂类化疗的患者。
结论
43.9%的患者出现疾病复发，铂类/紫杉醇联合化疗加放疗似乎是最佳辅助治疗方案。
Zotero 插件